Home / About us / Leadership / Eric Hoffman, PhD
Eric Hoffman, PhD
Co-founder, CEO
Dr. Hoffman received his PhD in Drosophila genetics at Johns Hopkins University, then began working on Duchenne muscular dystrophy as a post-doctoral fellow with Dr. Louis Kunkel at Boston Children’s Hospital and Harvard Medical School. He has held faculty positions at the University of Pittsburgh School of Medicine, George Washington University, and is currently Professor of Pharmaceutical Sciences and Associate Dean for Research at the School of Pharmacy and Pharmaceutical Sciences at Binghamton University – State University of New York.
While serving as Director of Research Center for Genetic Medicine at Children’s National Medical Center (1990-2016), Dr. Hoffman established infrastructure for translational research in neuromuscular disease, including founding the Cooperative International Neuromuscular Research Group (CINRG; www.cinrgresearch.org), and co-founded three companies that spun off from these efforts (TRiNDS LLC [www.trinds.com], ReveraGen BioPharma [www.reveragen.com], and AGADA BioPharma). Dr. Hoffman’s published research work can be found here.
Dr. Hoffman took on the CEO role from Dr. Nagaraju in 2022, as Dr. Nagaraju became Dean of the School of Pharmacy and Pharmaceutical Sciences at Binghamton University, State University of New York. Dr. Hoffman oversees all operations at AGADA, with a particular focus on clinical trial support (trial design, endpoints, muscle biopsy procedures and methods, and biomarker outcomes). He works with clients and the expert AGADA team on a day-to-day basis, providing guidance, consulting, data interpretation and sign off on all clinical studies.
Dr. Hoffman has extensive experience with nuances of placement of biomarkers in drug development programs (context of use), ensuring that biomarker assays are appropriate as outcomes in trials (fit for purpose), as well as deep knowledge of the technical aspects of muscle biopsies and data interpretation. He brings this knowledge and experience to client projects and trials to help ensure robust data in support of regulatory programs.
Get in touch
To learn how AGADA Biosciences could support your program, get in touch with our team and start the conversation.
How we work
We bring an agile, collaborative and responsive approach to every engagement, shaping our support around the needs of your program rather than a rigid process. Whether you engage us at a single stage or across multiple points in development, we work to de-risk programs, protect data integrity and help your teams progress with confidence.
1
Refined for your program:
We shape our approach around the needs of each program, not the other way around.
2
Direct access to senior experts:
Our lean model keeps scientific expertise close to the work and communication clear.
3
Built to de-risk progress:
We help you de-risk development through rigorous science and practical support.
4
Protecting data integrity:
Our work is designed to support reliable outputs and maintain confidence in the data.
Why AGADA?
We bring dedicated expertise to programs where there is little room for error, providing the scientific support, responsiveness and program fit that help rare disease teams move forward with clarity.
Decade of specialization:
Founded in 2013 as a spinout from Children’s National Medical Center to provide specialist scientific support for rare disease drug development.
Consistent audit success:
We successfully pass an average of five sponsor audits annually to support clinical trials across multiple phases.
Historical benchmarking:
We leverage archival data from over 100 trials in mouse models of muscular dystrophy to accurately power your efficacy studies.
Dedicated scale:
We operate with a team of approximately 50 employees, entirely focused on executing complex rare disease programs.
Meet more of the leadership team
